MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel <i>MET</i> R1004G Mutation
Lisa P. Chu(Brigham and Women's Hospital), Jonathan W. Riess(University of California Davis Medical Center), Christine A. Parachoniak(Foundation Medicine (United States)), Michael G. Moore(Indiana University School of Medicine), D. Gregory Farwell(University of California, Davis), Jeffrey S. Ross(Unknown), Siraj M. Ali(UPMC Hillman Cancer Center), Andreas Heilmann(Foundation Medicine (United States)), Shyam Rao(UC Davis Comprehensive Cancer Center), Vincent A. Miller(Universidad San Carlos), Debra Franck(Boston Children's Hospital), Jeffrey P. Gregg(University of California Davis Medical Center), Rachel Erlich(Broad Institute)
Cited by 7
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
|Journal of Clinical Oncology|2004|1.7k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k